Article
Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.
British journal of cancer - 1 Jun 2024
Tian Yu, Lin Yi, Qu Conghui, Arndt Volker, Baurley James W, Berndt Sonja I, Bien Stephanie A, Bishop D Timothy, Brenner Hermann, Buchanan Daniel D, Budiarto Arif, Campbell Peter T, Carreras-Torres Robert, Casey Graham, Chan Andrew T, Chen Rui, Chen Xuechen, Conti David V, Díez-Obrero Virginia, Dimou Niki, Drew David A, Figueiredo Jane C, Gallinger Steven, Giles Graham G, Gruber Stephen B, Gunter Marc J, Harlid Sophia, Harrison Tabitha A, Hidaka Akihisa, Hoffmeister Michael, Huyghe Jeroen R, Jenkins Mark A, Jordahl Kristina M, Joshi Amit D, Keku Temitope O, Kawaguchi Eric, Kim Andre E, Kundaje Anshul, Larsson Susanna C, Marchand Loic Le, Lewinger Juan Pablo, Li Li, Moreno Victor, Morrison John, Murphy Neil, Nan Hongmei, Nassir Rami, Newcomb Polly A, Obón-Santacana Mireia, Ogino Shuji, Ose Jennifer, Pardamean Bens, Pellatt Andrew J, Peoples Anita R, Platz Elizabeth A, Potter John D, Prentice Ross L, Rennert Gad, Ruiz-Narvaez Edward A, Sakoda Lori C, Schoen Robert E, Shcherbina Anna, Stern Mariana C, Su Yu-Ru, Thibodeau Stephen N, Thomas Duncan C, Tsilidis Konstantinos K, van Duijnhoven Franzel J B, Van Guelpen Bethany, Visvanathan Kala, White Emily, Wolk Alicja, Woods Michael O, Wu Anna H, Peters Ulrike, Gauderman W James, Hsu Li, Chang-Claude Jenny
Abstract excerpt
BACKGROUND: Menopausal hormone therapy (MHT), a common treatment to relieve symptoms of menopause, is associated with a lower risk of colorectal cancer (CRC). To inform CRC risk prediction and MHT risk-benefit assessment, we aimed to evaluate the joint association of a polygenic risk score (PRS) for CRC and MHT on CRC risk. METHODS: We used data from 28,486 postmenopausal women (11,519 cases and 16,967 controls)...
Read the complete abstract on PubMed